{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:04:01Z","timestamp":1782180241698,"version":"3.54.5"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Health Security"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:p>The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat, building flexible capabilities for rapid medical countermeasure (MCM) development, and exercising, maintaining, and improving those response capabilities. The Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of MCMs in response to natural and manmade threats. In this article, the authors describe a BARDA threat assessment tool that, in conjunction with other factors, facilitates portfolio management and decisionmaking related to the advanced development of MCMs for emerging infectious diseases. The tool was designed to use readily accessible public data and information related to the threat posed by pathogens. It can be adjusted to modify the specific areas of interest (eg, removal\/addition of parameters) to facilitate cross-pathogen analysis and can be updated to reflect changes (eg, new outbreak) that may impact the overall threat assessment. Finally, assessment of certain pathogens is included.<\/jats:p>","DOI":"10.1089\/hs.2024.0076","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:17:21Z","timestamp":1738225041000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-692X","authenticated-orcid":false,"given":"Richard C.","family":"White","sequence":"first","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Chandran","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Adams","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla A.","family":"Britson","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Cao","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dale","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Eisnor","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Erlandson","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Fredericksen","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan J.","family":"Fritch","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushyannah","family":"Killens-Cade","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malen A.","family":"Link","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Little","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Michalik","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Robertson","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rowe","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley L.","family":"Sciarretta","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomi","family":"Tong","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Divisi..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Pandemic and All-Hazards Preparedness Act Pub L No. 109-417 120 Stat 2831 (2006). Accessed October 18 2024. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-109publ417\/pdf\/PLAW-109publ417.pdf"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2001.0888"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1112.050997"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06536"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2024.0074"},{"key":"e_1_3_2_7_2","unstructured":"Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. Platform Technology Designation Program for Drug Development: Draft Guidance for Industry. Washington DC: US Food and Drug Administration; 2024. Accessed October 15 2024. https:\/\/www.fda.gov\/media\/178938\/download"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2129930"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01098-9"},{"key":"e_1_3_2_10_2","unstructured":"US Centers for Disease Control and Prevention. Bioterrorism agents\/diseases. Accessed September 12 2024. https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp"},{"key":"e_1_3_2_11_2","unstructured":"World Health Organization. Prioritizing diseases for research and development in emergency contexts. Accessed July 12 2024. https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac296"},{"key":"e_1_3_2_13_2","unstructured":"Coalition for Epidemic Preparedness Innovations. Priority pathogens. Accessed October 15 2024. https:\/\/cepi.net\/priority-pathogens"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.009"},{"key":"e_1_3_2_15_2","unstructured":"Africa Centres for Disease Control and Prevention (Africa CDC). Risk Ranking and Prioritization of Epidemic-Prone Diseases. Addis Ababa Ethiopia: Africa CDC; 2022. Accessed July 12 2024. https:\/\/africacdc.org\/download\/risk-ranking-and-prioritization-of-epidemic-prone-diseases\/"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102676"},{"key":"#cr-split#-e_1_3_2_17_2.1","unstructured":"Biomedical Advanced Research and Development Authority (BARDA). BARDA Strategic Plan: 2022\u20102026. Washington DC: Administration for Strategic Preparedness and Response"},{"key":"#cr-split#-e_1_3_2_17_2.2","unstructured":"2022. Accessed October 15 2024. https:\/\/medicalcountermeasures.gov\/media\/38717\/barda-strategic-plan-2022-2026.pdf"},{"key":"e_1_3_2_18_2","unstructured":"118 Cong Rec H1893 (daily ed. March 22 2024). Accessed October 18 2024. https:\/\/www.congress.gov\/118\/crec\/2024\/03\/22\/170\/51\/CREC-2024-03-22-pt2-PgH1501.pdf"},{"key":"e_1_3_2_19_2","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). NIAID biodefense pathogens. Last reviewed June 13 2024. Accessed July 12 2024. https:\/\/www.niaid.nih.gov\/research\/niaid-biodefense-pathogens"},{"key":"e_1_3_2_20_2","unstructured":"Administration for Strategic Preparedness and Response (ASPR). Public Health Emergency Medical Countermeasure Enterprise: Strategy and Implementation Plan 2022. Washington DC: ASPR; 2022. Accessed October 15 2024. https:\/\/aspr.hhs.gov\/PHEMCE\/2022-SIP\/Documents\/PHEMCE-SIP-2022-508.pdf"},{"key":"e_1_3_2_21_2","unstructured":"Biomedical Advanced Research and Development Authority (BARDA). FDA approvals licensures & clearances for BARDA supported products. Accessed July 31 2024. https:\/\/medicalcountermeasures.gov\/barda\/fdaapprovals"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.40.18996-en"},{"key":"e_1_3_2_23_2","unstructured":"World Health Organization. 2018 Annual review of diseases prioritized under the Research and Development Blueprint. Published February 6-7 2018. Accessed October 15 2024. https:\/\/www.who.int\/news-room\/events\/detail\/2018\/02\/06\/default-calendar\/2018-annual-review-of-diseases-prioritized-under-the-research-anddevelopment-blueprint"},{"key":"e_1_3_2_24_2","unstructured":"US Centers for Disease Control and Prevention. Estimated US flu disease burden. Accessed October 15 2024. https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis\/2023-2024.html"}],"container-title":["Health Security"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hs.2024.0076","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hs.2024.0076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hs.2024.0076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:41:28Z","timestamp":1777452088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hs.2024.0076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,1]]}},"alternative-id":["10.1089\/hs.2024.0076"],"URL":"https:\/\/doi.org\/10.1089\/hs.2024.0076","relation":{},"ISSN":["2326-5094","2326-5108"],"issn-type":[{"value":"2326-5094","type":"print"},{"value":"2326-5108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}